

Supplemental Table: Multivariate associations with 30-day MACE and 12-month mortality in the entire STEMI cohort

	30-day MACE			12-month mortality		
	OR	95% CI	<i>P value</i>	OR	95% CI	<i>P value</i>
Age, each year increase	1.01	1.00 - 1.02	<i>0.03</i>	1.03	1.02 - 1.05	<i><0.001</i>
Female sex	1.08	0.85 - 1.38	<i>0.52</i>	1.17	0.89 - 1.54	<i>0.26</i>
Diabetes	1.07	0.82 - 1.39	<i>0.61</i>	1.15	0.85 - 1.55	<i>0.37</i>
Previous CABG or PCI	1.41	1.09 - 1.82	<i>0.009</i>	1.20	0.98 - 0.99	<i>0.26</i>
Pre-procedural eGFR	0.99	0.99 - 0.99	<i><0.001</i>	0.98	0.98 - 0.99	<i><0.001</i>
Cardiogenic shock or cardiac arrest requiring intubation	7.76	6.21 - 9.68	<i><0.001</i>	10.09	7.78 - 13.08	<i><0.001</i>
Severe LVEF impairment	4.71	3.53 - 6.30	<i><0.001</i>	7.49	5.31 - 10.54	<i><0.001</i>
Symptom onset in-hospital	1.91	1.38 - 2.64	<i><0.001</i>	1.88	1.29 - 2.73	<i><0.001</i>

CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; MACE, major adverse cardiovascular events; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; STEMI, ST elevation myocardial infarction;

STEMI cohort included in this analysis is only those patients who presented within 12 hours and without inter-hospital transfer.